T2 Biosystems, a company developing direct detection products enabling
superior diagnostics, today announced the presentation of new data on
hemostasis monitoring at the American Association for Clinical Chemistry
Annual Meeting, July 15-19, 2012, in Los Angeles, CA. T2Hemostasis is
the first platform capable of rapidly characterizing key coagulation,
platelet and other hematologic factors directly from whole blood on a
single, compact instrument. The data presented at AACC demonstrate that
T2Hemostasis provides reliable and rapid results when compared to
"T2Hemostasis, which utilizes the company's proprietary T2MR detector,
is able to monitor several key hemostasis measurements, including
clotting time, platelet activity, fibrinolysis and hematocrit, on a
single assay in minutes," said John McDonough, CEO, T2 Biosystems. "T2
Bio's approach could enable more effective decisions for anticoagulation
and anti-platelet therapies, as well as the selection of appropriate
transfusion products during cardiovascular procedures. The benefits of
improved hemostasis monitoring and therapeutic decision-making have a
tremendous potential impact on the cost and quality of healthcare."
The presentation entitled "Characterization of new real-time hemostasis
monitoring device for multiplexed detection of PT/INR, platelet
activity, fibrinolysis, and hematocrit" was authored by T.J. Lowery, V.
Papkov, E.C. Thayer, C. Rittershaus and V. Demas. The T2Hemostasis assay
was used to demonstrate correlations with established methods for
measuring PT/INR (n>40, R2>0.9), clotting time (n>20, R2>0.8),
platelet activity (n>12, R2>0.9), fibrinolysis>2>0.75)
and hematocrit (n>20, R2>0.9) using human plasma and blood
samples. Additionally, rapid and direct measurement of effectiveness of
anti-platelet drugs, such as Aspirin and Abciximab, was reported.
T2Hemostasis provides rapid, real-time multiplexed monitoring with small
sample volumes (<40 µL) of blood or plasma, down to a fingerstick test
on a low cost and compact device.